IP Verse

Solid Forms Comprising (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione, Compositions Thereof, And Uses Thereof - EP2687213

The patent EP2687213 was granted to Amgen Europe on Jul 17, 2019. The application was originally filed on Mar 27, 2008 under application number EP13182315A. The patent is currently recorded with a legal status of "Revoked".

EP2687213

AMGEN EUROPE
Application Number
EP13182315A
Filing Date
Mar 27, 2008
Status
Revoked
Feb 19, 2021
Publication Date
Jul 17, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMar 19, 2020ELKINGTON AND FIFEADMISSIBLE

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS3536809
DESCRIPTIONUS3598123
DESCRIPTIONUS3845770
DESCRIPTIONUS3916899
DESCRIPTIONUS4008719
DESCRIPTIONUS5059595
DESCRIPTIONUS5073543
DESCRIPTIONUS5120548
DESCRIPTIONUS5354556
DESCRIPTIONUS5591767
DESCRIPTIONUS5639476
DESCRIPTIONUS5674533
DESCRIPTIONUS5733566
DESCRIPTIONUS6020358
DESCRIPTIONUS6962940
SEARCHUS2008027123
SEARCHWO03080049

Non-Patent Literature (NPL) Citations (50) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- AU ET AL., BRIT. J. PHARM., (1998), vol. 123, pages 1260 - 1266
DESCRIPTION- BAEHR ET AL., J. BIOL. CHEM., (1979), vol. 254, page 11669
DESCRIPTION- BAUGHMAN ET AL., J. LAB. CLIN. MED, (1990), vol. 115, pages 36 - 42
DESCRIPTION- BEAVO; REITSNYDER, TRENDS IN PHARM., (1990), vol. 11, pages 150 - 155
DESCRIPTION- BERTOLINI ET AL., NATURE, (1986), vol. 319, pages 516 - 518
DESCRIPTION- BISSONNETTE ET AL., INFLAMMATION, (1989), vol. 13, pages 329 - 339
DESCRIPTION- BLOOM; BEAVO, PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, pages 14188 - 14192
DESCRIPTION- CLOUSE ET AL., J. IMMUNOL., (1989), vol. 142, pages 431 - 438
DESCRIPTION- CORRAL ET AL., MOL. MED, (1996), vol. 2, pages 506 - 515
DESCRIPTION- DERIAN ET AL., J IMMUNOL., (1995), vol. 154, pages 308 - 3 17
DESCRIPTION- DERIAN ET AL., J. IMMUNOL., (1995), vol. 154, pages 308 - 317
DESCRIPTION- DEZUBE ET AL., LANCET, (1990), vol. 335, page 662
DESCRIPTION- DUH ET AL., PROC. NAT. ACAD. SCI., (1989), vol. 86, pages 5974 - 5978
DESCRIPTION- ELLIOT ET AL., INT. J PHARMAC, (1995), vol. 17, pages 141 - 145
DESCRIPTION- FERRAI-BALIVIERA ET AL., ARCH. SURG, (1989), vol. 124, pages 1400 - 1405
DESCRIPTION- FOLKS ET AL., PNAS, (1989), vol. 86, pages 2365 - 2368
DESCRIPTION- GILLESPIE ET AL., MOL. PHARM., (1989), vol. 36, page 773
DESCRIPTION- GRAU ET AL., N. ENGL. J. MED., (1989), vol. 320, pages 1586 - 1591
DESCRIPTION- HATZELMANN; SCHUDT, J. PHARM. EXP. THER., (2001), vol. 297, pages 267 - 279
DESCRIPTION- HIDAKA; ASANO, BIOCHEM. BIOPHYS. ACTA, (1976), vol. 429, page 485
DESCRIPTION- HINSHAW ET AL., CIRC. SHOCK, (1990), vol. 30, pages 279 - 292
DESCRIPTION- HOLLER ET AL., BLOOD, (1990), vol. 75, pages 1011 - 1016
DESCRIPTION- JENS T. CARSTENSEN, Drug-Stability: Principles & Practice, 2d. Ed.,, MARCEL DEKKER, (1995), pages 379 - 80
DESCRIPTION- JOHNSON ET AL., ENDOCRINOLOGY, (1989), vol. 124, pages 1424 - 1427
DESCRIPTION- LIST ET AL., J CLIN. ONCOL., (1990), vol. 8, page 1424
DESCRIPTION- LOWE; CHENG, DRUGS OF THE FUTURE, (1992), vol. 17, no. 9, pages 799 - 807
DESCRIPTION- LOWE, EXP. OPIN. THER. PATENTS, (1998), vol. 8, pages 1309 - 1332
DESCRIPTION- L. YU, ADV. DRUG. DELIV. REV., (2001), vol. 48, pages 27 - 42
DESCRIPTION- MANFRED E. WOLFF, Burger's Medicinal Chemistry and Drug Discovery, 5th ed., (1995), vol. 172-178, pages 949 - 982
DESCRIPTION- MILLAR ET AL., LANCET, (1989), vol. 2, pages 712 - 714
DESCRIPTION- MONTO ET AL., BLOOD, (1990), vol. 79, page 2670
DESCRIPTION- MULLER ET AL., BIOORG. & MED. CHEM. LETT, (1998), vol. 8, pages 2669 - 2674
DESCRIPTION- MULLER ET AL., BIOORG. & MED. CHEM. LETT., (1998), vol. 8, pages 2669 - 2674
DESCRIPTION- MULLER ET AL., BIOORG. & MED CHEM. LETT., (1999), vol. 9, pages 1625 - 1630
DESCRIPTION- MULLER ET AL., J. MED CHEM., (1996), vol. 39, page 3238
DESCRIPTION- NICHOLSEN ET AL., TRENDS PHARMACO. SCI., (1991), vol. 12, page 19
DESCRIPTION- PIGNET ET AL., NATURE, (1990), vol. 344, pages 245 - 247
DESCRIPTION- POLI ET AL., PROC. NATL. ACAD. SCI., (1990), vol. 87, pages 782 - 784
DESCRIPTION- POLL ET AL., AIDS RES. HUM. RETROVIRUS, (1992), pages 191 - 197
DESCRIPTION- POLL, PROC. NAT. ACAD. SCI., (1990), vol. 87, pages 782 - 785
DESCRIPTION- RICE ET AL., SCIENCE, (1989), vol. 246, pages 1303 - 1306
DESCRIPTION- S. R. CHEMBURKAR ET AL., ORG. PROCESS RES. DEV., (2000), vol. 4, pages 413 - 417
DESCRIPTION- S. R. VIPPAGUNTA ET AL., ADV. DRUG. DELIV. REV., (2001), vol. 48, pages 3 - 26
DESCRIPTION- The Merck Manual 17th ed., (1999), vol. 953
DESCRIPTION- The United States Pharnlacageia 23rd ed., (1995), pages 1843 - 1844
DESCRIPTION- TIERNEY ET AL, Current Medical Diagnosis & Treatment, APPLETON & LANGE, (1998), page 499
DESCRIPTION- TRACEY ET AL., NATURE, (1987), vol. 330, pages 662 - 664
DESCRIPTION- VERGHESE ET AL., J. PHARM. EXPER. THERAPEUT., (1995), vol. 272, no. 3, pages 1313 - 1320
DESCRIPTION- VON DULLEMEN ET AL., GASTROENTEROLOGY, (1995), vol. 109, pages 129 - 135
SEARCH- GRANT D J W, "THEORY AND ORIGIN OF POLYMORPHISM", POLYMORPHISM IN PHARMACEUTICAL SOLIDS, XX, XX, (19990101), pages 1 - 10, XP008050146 [A] 1-15 * the whole document *

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents